KM Research Hub
← 返回论文库
无 KM 图 入排:待复核 图源:可得 入排置信度 0.45

Single-cell dissection of persistent tumor antigens in non-responders reveals opportunities for TAA-targeted vaccination after neoadjuvant therapy in esophageal squamous cell carcinoma.

Ruixiang Zhang, Shu Qi, Yang Zhou, Ying Hu, Yang Li, Yue Li, Jianjun Qin, Ai-Rong Yang, Henghui Zhang, Zhihua Liu, Yin Li

J Immunother Cancer 14(4) e014562

PMID42019971
PMCIDPMC13110702
DOI10.1136/jitc-2025-014562
发表日期2026-04-22
入排依据:The record describes an original, human, randomized, Phase III, drug-intervention oncology trial. However, it does not report a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier). The study's primary endpoint appears to be pathological response and immune/tumor microenvironment analysis, not survival or progression. Therefore, eligibility cannot be confirmed based on the provided abstract.
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 7 张 PubMed Figure,均未识别为 KM 图:Figure 1:研究设计图;Figure 2:图注未提示 KM 曲线;Figure 3:图注未提示 KM 曲线;Figure 4:图注未提示 KM 曲线;Figure 5:图注未提示 KM 曲线;另有 2 张未列出。
摘要

摘要

BACKGROUND: Neoadjuvant immune checkpoint blockade (ICB) combined with chemotherapy has demonstrated higher response rates than chemotherapy alone in resectable esophageal squamous cell carcinoma (ESCC). Although tumor microenvironment (TME) features associated with treatment response have been studied in the contexts of both chemotherapy and immunotherapy, direct comparisons of these characteristics and their implications for novel therapeutic development remain largely unexplored. METHODS: Paired pretreatment and post-treatment tumor samples were prospectively collected from 55 patients with locally advanced ESCC enrolled in a multicenter, phase 3 clinical trial (ChiCTR2000040034). Patients were randomized to receive neoadjuvant chemotherapy (paclitaxel with cisplatin, TP; n=14) or its combination with PD-1 blockade (camrelizumab, albumin-bound paclitaxel and cisplatin/paclitaxel and cisplatin, Cam+nab-TP/TP; n=41), followed by surgical resection. Pathological response was defined based on Mandard's Tumor Regression Grade scoring system. Changes in immune cell populations and tumor-associated antigens (TAAs) within the TME in relation to response were characterized using single-cell RNA and T cell receptor sequencing. RESULTS: Both chemotherapy and chemoimmunotherapy responders exhibited shared temporal dynamics including dendritic cell remodeling, cytotoxic CD8+ T cell contraction, and memory T cell expansion, with chemoimmunotherapy uniquely suppressing the clonal expansion of GZMB+TIGIT+ T cells. In contrast, non-responders failed to elicit effective antitumor immunity and displayed persistent expression of targetable TAAs, fully preserved HLA machinery, and clonal expansion of dysfunctional GZMB+TIGIT+ T cells. CONCLUSIONS: Our study identifies key immune contributors correlated with response to neoadjuvant therapies and a panel of TAAs in non-responders. These findings support the development of TAA-targeted therapeutic vaccines and combination strategies incorporating ICB to overcome resistance in non-responders.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(7,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Overview of cellular composition of ESCC before and after neoadjuvant therapies. ( A ) Study design and workflow. Created with BioGDP.com. ( B ) Uniform Manifold Approximation and Projection (UMAP) visualization of high-quality cells (n=784 315) captured from all enrolled samples (n=86), colored by cell type. Cell types were identified based on the expression of canonical markers and top differentially expressed genes (DEGs) defining each cluster, as shown in online supplemental figure S1A. ( C ) Proportions of major cell types in pretreatment tumors, stratified by treatment group and clinical response. Combo: Cam+nab-TP/TP; Chemo: TP. ( D, E ) Comparisons of pretreatment and post-treatment changes in the proportion of major cell types between responders and non-responders from Cam+nab-TP/TP ( D ) or TP ( E ) cohort. Boxplots show the first to the third quartile with a line in the middle that represents the median. Whiskers represent 1.5-fold of the IQR. Data were transformed using the centered log-ratio (CLR) method prior to statistical analysis. P values were calculated using the Wilcoxon test and adjusted for multiple comparisons by the Benjamini-Hochberg (BH) method. Cam+nab-TP/TP, camrelizumab plus albumin-bound paclitaxel and cisplatin/paclitaxel and cisplatin; ESCC, esophageal squamous cell carcinoma; Pericyte/SMC, pericyte/smooth muscle cell; scRNA/TCR-seq, single-cell RNA and T cell receptor sequencing; TP, paclitaxel and cisplatin.
非 KM Figure
Figure 2Figure 2. Dynamics of myeloid cells in response to neoadjuvant therapies. ( A ) UMAP clustering and classification of myeloid cells (n=87 652). Subsets were identified based on the expression of canonical markers and top DEG defining each cluster, as shown in online supplemental figure S2A. ( B ) Proportions of myeloid cell subsets in pre-treatment tumors, stratified by treatment group and clinical response. Combo: Cam+nab-TP/TP; Chemo: TP. ( C, D ) Comparisons of pretreatment and post-treatment changes in the proportion of myeloid cell subsets between responders and non-responders from Cam+nab-TP/TP ( C ) or TP ( D ) cohort. Boxplots show the first to the third quartile with a line in the middle that represents the median. Data were transformed using the CLR method prior to statistical analysis. P values were calculated using the Wilcoxon test and adjusted for multiple comparisons by the BH method. BH, Benjamini-Hochberg; Cam+nab-TP/TP, camrelizumab+albumin-bound paclitaxel and cisplatin/paclitaxel and cisplatin; cDC, conventional dendritic cell; CLR, centered log-ratio; DEG, differentially expressed gene; Mac, macrophage; Mono, monocyte; NR, non-responder; pDC, plasmacytoid dendritic cell; R, responder; tDC, tolerogenic (regulatory) dendritic cell; TP, paclitaxel and cisplatin; UMAP, Uniform Manifold Approximation and Projection.
非 KM Figure
Figure 3Figure 3. Compositional and clonal dynamics of CD8 + T cells in response to neoadjuvant therapies. ( A ) UMAP clustering and classification of CD8 + T cells (n=204 941). Subsets were identified based on the expression of canonical markers and top DEGs defining each cluster, as shown in online supplemental figure S3A. ( B, C ) Comparisons of pre- and post-treatment changes in the proportion of CD8 + T subsets between responders and non-responders from Cam+nab-TP/TP ( B ) or TP ( C ) cohort. Boxplots show the first to the third quartile with a line in the middle that represents the median. Whiskers represent 1.5-fold of the IQR. Data were transformed using the CLR method prior to statistical analysis. P values were calculated using the Wilcoxon test and adjusted for multiple comparisons by the BH method. ( D ) UMAP color-coded by pseudotime trajectory analysis of CD8 + T cells. ( E ) Gene set enrichment analysis (GSEA) using the MSigDB Hallmark gene sets on genes ranked by log₂FC (post-treatment vs pre-treatment) in CD8 + T cell subsets that significantly decreased after neoadjuvant Cam+nab-TP/TP in pathological responders. Hallmark gene sets were used to compute enrichment scores. Bars show the normalized enrichment score (NES), and the color scale represents the –log10 p value. Statistical significance was assessed using permutation-based p values (10 000 permutations). ( F, G ) Treatment-induced clonal expansion of CD8 + T cell subsets in patients treated with Cam+nab-TP/TP ( F ) or TP ( G ). TCR clonotypes were categorized by comparing their abundance between pretreatment and post-treatment samples from the same patient. New: high abundance clones detected only after treatment; Expanded: clones with increased abundance after treatment. Left: responders; right: non-responders. ( H, J ) Circle plot showing outgoing ligand–receptor interactions from malignant epithelial cells to CD8 + T cell subsets in Cam+nab-TP/TP ( H ) or TP ( J ) non-responders. Edge width represents interaction strength and node size indicates the number of significant ligand–receptor pairs. ( I, K ) Bubble plot illustrating predicted ligand–receptor interactions from malignant epithelial cells to specific CD8 + T cell subsets in Cam+nab-TP/TP ( I ) or TP ( K ) non-responders. The color of each dot represents the interaction probability. Y-axis lists ligand–receptor pairs, and separate panels correspond to different CD8 + T cell subtypes. BH, Benjamini–Hochberg; Cam+nab-TP/TP, camrelizumab + albumin-bound paclitaxel and cisplatin/paclitaxel and cisplatin; CLR, centered log-ratio; gd-T, gamma delta T cell; DEGs, differential gene expressions; MAIT, mucosal-associated invariant T cell; NK, natural killer cell; NKT, natural killer T cell; NR, non-responder; R, responder; Tn/mem, naïve/memory T cell; TP, paclitaxel and cisplatin; Tprf, proliferation T cell; UMAP, Uniform Manifold Approximation and Projection.
非 KM Figure
Figure 4Figure 4. Expression of tumor-associated antigens (TAAs) in ESCC before and after neoadjuvant therapies. ( A ) Differential expression of the nine selected TAAs between ESCC tumors and matched normal adjacent tissues. Strategy for the selection is shown in online supplemental figure S4A. *p<0.05, ****p<0.0001 of Wilcoxon rank-sum test. Boxplots display median and IQR. ( B ) Heatmap illustrating the enrichment of nine selected TAAs in ESCC tumor tissues compared with a spectrum of normal tissues. ( C, D ) TAA-specific clearance in response to Cam+nab-TP/TP for responders ( C ) and non-responders ( D ). Heatmaps visualize the percentage of TAA-expressing cells (left) and the average TAA expression level (right). Top: pretreatment; bottom: post-treatment. ( E, F ) TAA-specific clearance in response to TP for responders ( E ) and non-responders ( F ). Cam+nab-TP/TP, camrelizumab+albumin-bound paclitaxel and cisplatin/paclitaxel and cisplatin; ESCC, esophageal squamous cell carcinoma; NR, non-responder; R, responder; TP, paclitaxel and cisplatin; TPM, transcripts per million.
非 KM Figure
Figure 5Figure 5. Expression of MHC class I genes in ESCC before and after neoadjuvant therapies. ( A, B ) Heatmap showing expression of MHC class I genes in pretreatment and post-treatment tumors from Cam+nab-TP/TP responders ( A ) and non-responders ( B ). Top: pretreatment; bottom: post-treatment. Left: percentages of tumor cells expressing each gene; right: average expression levels of each gene. ( C ) Comparisons of pretreatment and post-treatment changes in the percentages of tumor cells expressing each MHC class I gene between responders and non-responders in the Cam+nab-TP/TP cohort. Boxplots show the first to the third quartile with a line in the middle that represents the median. Whiskers represent 1.5-fold of the IQR. P values were calculated using the Wilcoxon test and adjusted for multiple comparisons by the BH method. ( D ) Comparisons of pre- and post-treatment changes in the average expression level of each MHC class I gene between responders and non-responders in the Cam+nab-TP/TP cohort. ( E, F ) Heatmap showing expression of MHC class I genes in pre- and post-treatment tumors from TP responders ( E ) and non-responders ( F ). Top: pretreatment; bottom: post-treatment. Left: percentages of tumor cells expressing each gene; right: average expression levels of each gene. ( G ) Comparisons of pretreatment and post-treatment changes in the percentages of tumor cells expressing each HLA class I gene between responders and non-responders in the TP cohort. ( H ) Comparisons of pretreatment and post-treatment changes in the average expression level of each MHC class I gene between responders and non-responders in the TP cohort. BH, Benjamini-Hochberg; major histocompatibility complex; Cam+nab-TP/TP, camrelizumab+albumin-bound paclitaxel and cisplatin/paclitaxel and cisplatin; ESCC, esophageal squamous cell carcinoma; NR, non-responder; R, responder; TP, paclitaxel and cisplatin.
非 KM Figure
Figure 6Figure 6. Dynamics of TME in responders and non-responders following neoadjuvant therapies. Responders exhibit active antitumor responses characterized by dendritic cell (DC) activation, exhausted CD8 + T cell contraction, and memory T cell expansion, leading to cancer elimination. Conversely, non-responders show a GZMB + TIGIT + T cell expansion and persistent expression of targetable TAAs with intact HLA machinery. These vulnerabilities could be targeted by a comprehensive triplet combination vaccination strategy that integrates TAA/neoantigen prediction, DC loading, and PD-1 blockade. Created with BioGDP.com. HLA, human leukocyte antigen; PD-1, programmed cell death protein 1; PD-L1, programmed cell death-ligand 1; TAA, tumor-associated antigen; TCR, T cell receptor; TME, tumor microenvironment.
非 KM Figure
Figure 7Figure 7. Summary of individual TME characteristics before and after neoadjuvant therapies in the entire ESCC cohort. Cam+nab-TP/TP, camrelizumab + albumin-bound paclitaxel and cisplatin/paclitaxel and cisplatin; cDC, conventional dendritic cell; ESCC, esophageal squamous cell carcinoma; Mac, macrophage; MAIT, mucosal-associated invariant T cell; Mono, monocyte; NR, non-responder; pDC, plasmacytoid DC; Pericyte/SMC, pericyte/smooth muscle cell; R, responder; TAA, tumor-associated antigen; TME, tumor microenvironment; MHC, major histocompatibility complex; Tn/mem, naïve/memory T cell; TP, paclitaxel and cisplatin; Tprf, proliferation T cell; tDC, tolerogenic (regulatory) DC.
非 KM Figure